Recruiting
Phase 2

TigerPaw System

Sponsor:

LAAx, Inc.

Code:

NCT00962702

Conditions

Stroke

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

LAAx TigerPaw System

Study Details

Brief summary:

The dual primary safety and effectiveness outcomes for the use of The TigerPaw System include the rate of device related adverse and serious adverse events and the extent of complete exclusion of the LAA with minimal residual cavity.

Conditions

Stroke

Study ID

NCT00962702

Start date

Aug, 2009

Status verified date

Aug, 2009

Completion date

Oct, 2010

Anticipated

Primary completion date

Dec, 2009

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Greater than or equal to 18 years of age
2. Stroke Risk (CHADS score > or = 2, CHADS scoring: CHF = 1 pt, Hypertension (or treated hypertension) = 1 pt, Age > 75 = 1 pt, Diabetes = 1 pt, Prior stroke or TIA = 2 pts)
3. Subject scheduled to undergo elective non-endoscopic cardiac surgical procedure(s) including cardiac surgery for one or more of the following:

  • mitral valve repair or replacement
  • aortic valve repair or replacement
  • tricuspid valve repair or replacement
  • coronary artery bypass procedures
  • concomitant surgical (ablation or cut and sew) Maze procedure
4. Ejection fraction > 30%
5. Absence of thrombus in LAA
6. During open procedure, LAA anatomy is determined to be suitable for closure
7. life expectancy of > 1 year
8. patient willingness to cooperate with follow-up tests
9. Informed Consent

Exclusion Criteria:

1. Previous cardiac surgery
2. Contraindication to Transesophageal Echocardiography (TEE)
3. Thrombus in the LAA/LA
4. NYHA Class IV heart failure symptoms
5. Need for emergent cardiac surgery (e.g., cardiogenic shock)
6. Creatinine > 200 umol/L
7. Current diagnosis of active systemic infection
8. Renal failure requiring dialysis or hepatic failure
9. A known drug and/or alcohol addiction
10. mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study and to cooperate with follow-up requirements
11. Preoperative need for an intra-aortic balloon pump or intravenous inotropes
12. Treatment with thoracic radiation
13. Concurrent chemotherapy
14. Long term treatment with steroids not including intermittent use of inhaled steroids for respiratory diseases
15. Known connective tissue disorders
16. Coagulation disorders
17. Any active medical condition that would preclude the patient from completing the study or would result in an unreasonable risk
18. Active participation in another clinical trial.
19. Intraoperative:

  • LAA is not appropriate for exclusion based upon intraoperative evaluations
  • Presence of thrombus in LAA or LA; or
  • Any other findings by surgeon/investigator that would preclude use of device

Study Design

Enrollment

60 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Exclusion of Left Atrial Appendage

Exclusion of Left Atrial Appendage

Interventions

LAAx TigerPaw System

Exclusion of Left Atrial Appendage

Primary outcome measure

  • The dual primary safety and effectiveness outcomes include the rate of device related adverse and serious adverse events and the extent of complete exclusion of the LAA with minimal residual cavity. [ Time Frame: Patients will be evaluated at 30 days post surgery and at 90 days post surgery. ]

Central Contacts and Locations

Central contacts

Locations

Clarian Health / Methodist Hospital

Recruiting

Indianapolis, Indiana, United States

Principal Investigator:

Arthur Coffee, MD

More Information

Sponsor

LAAx, Inc.

Last update posted

Aug 20, 2009

Last verified

Aug, 2009

Keywords

  • Exclusion
  • Left Atrial Appendage
  • Surgical
  • Open chest

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by LAAx, Inc. on 2009-08-20.